Platform
Changing how neurodegenerative diseases are treated – with Therapeutic Targeting (THETA™)
One of the biggest challenges in treating neurodegenerative disorders like Alzheimer’s disease is the difficulty of delivering drugs across the blood-brain barrier (BBB). Traditional biologic therapies have virtually no ability to cross the BBB, leaving patients with few effective options.
Transferrin receptor (TfR) shuttling is a validated mechanism for delivering large molecule drugs across the BBB, enabling dramatically higher drug concentration inside the brain. This advancement has the potential to fundamentally change the way we treat Alzheimer’s disease, but may also unlock new possibilities for novel therapeutics in other neurological diseases and beyond.
Therapeutic Targeting (THETA™) is distinct from other BBB-penetrant shuttles in development. By leveraging proven biology and precision antibody engineering, THETA is designed to enable the development of safer, more effective, and more convenient therapies that can achieve meaningful CNS exposure to better treat neurodegenerative diseases like Alzheimer’s.
THETA is engineered to overcome the limitations of other BBB-penetrant shuttle technologies. With patients in mind, we aim to bring best-in-class efficacy and safety in a convenient subcutaneous therapy.
